Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANGNNASDAQ:NEXINASDAQ:SNSENASDAQ:TH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGNAngion Biomedica$6.48$0.46▼$2.04$30.11M0.686,718 shs224,800 shsNEXINexImmune$3.43-5.8%$5.65$1.25▼$28.69$5M1.8437,922 shs6,761 shsSNSESensei Biotherapeutics$1.00+7.5%$0.96$0.51▼$1.72$23.34M0.1789,154 shs85,180 shsTHTarget Hospitality$10.81-1.7%$9.87$8.49▼$16.80$1.09B2.09571,758 shs525,824 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGNAngion Biomedica0.00%0.00%0.00%0.00%-86.94%NEXINexImmune-5.90%-1.15%-39.18%-33.78%-64.59%SNSESensei Biotherapeutics+7.18%+0.97%-14.73%+30.91%-36.85%THTarget Hospitality-1.73%+2.61%+21.19%+14.15%-16.85%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANGNAngion BiomedicaN/AN/AN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics3.9701 of 5 stars3.53.00.04.80.01.71.3THTarget Hospitality1.5277 of 5 stars1.35.00.00.01.11.72.5Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANGNAngion BiomedicaN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/ASNSESensei Biotherapeutics3.00Buy$4.00300.92% UpsideTHTarget Hospitality2.50Moderate Buy$11.001.76% UpsideCurrent Analyst RatingsLatest SNSE, ANGN, NEXI, and TH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$13.00 ➝ $12.003/26/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.003/25/2024THTarget HospitalityOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $10.003/14/2024THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $13.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANGNAngion Biomedica$2.30M0.00N/AN/A$1.32 per share0.00NEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/ATHTarget Hospitality$563.61M1.93$2.48 per share4.36$3.71 per share2.91Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANGNAngion Biomedica-$38.81MN/A0.00N/AN/AN/A-47.53%-40.55%N/ANEXINexImmune-$32.34M-$30.89N/A∞N/AN/A-247.17%-167.39%5/20/2024 (Estimated)SNSESensei Biotherapeutics-$34.10M-$1.22N/AN/AN/AN/A-44.01%-38.58%5/14/2024 (Estimated)THTarget Hospitality$173.70M$1.547.0215.671.1429.53%53.91%24.85%5/14/2024 (Estimated)Latest SNSE, ANGN, NEXI, and TH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023THTarget Hospitality$0.24$0.29+$0.05$0.29$118.00 million$126.20 million 2/28/2024Q4 2023SNSESensei Biotherapeutics-$0.32-$0.30+$0.02-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANGNAngion BiomedicaN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANGNAngion BiomedicaN/A20.0020.00NEXINexImmuneN/A1.061.06SNSESensei Biotherapeutics0.0111.9211.92THTarget Hospitality0.472.572.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANGNAngion Biomedica17.00%NEXINexImmune9.85%SNSESensei Biotherapeutics10.50%THTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipANGNAngion Biomedica19.70%NEXINexImmune19.40%SNSESensei Biotherapeutics25.50%THTarget Hospitality68.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANGNAngion Biomedica330.11 million24.18 millionNot OptionableNEXINexImmune221.37 million1.11 millionNot OptionableSNSESensei Biotherapeutics2825.07 million18.68 millionNot OptionableTHTarget Hospitality984100.52 million31.87 millionNot OptionableSNSE, ANGN, NEXI, and TH HeadlinesSourceHeadlineBCCP highlights opportunities in travel industry in '4th Travel Talks'msn.com - April 23 at 9:25 PMAston Villa 3-1 AFC Bournemouthavfc.co.uk - April 23 at 9:25 PMJason P. Vlacich Implements A Sell Strategy: Offloads $582K In Target Hospitality Stockbenzinga.com - April 16 at 12:41 PM1,349,167 Shares in Target Hospitality Corp. (NASDAQ:TH) Bought by Voss Capital LLCmarketbeat.com - April 15 at 7:42 PMTarget Hospitality (NASDAQ:TH) Earns Hold Rating from Stifel Nicolausamericanbankingnews.com - April 14 at 4:50 AMBournemouth vs Man Utd live: Score and latest updates from Vitality Stadiummsn.com - April 13 at 11:02 PMVanguard Group Inc. Acquires 523,398 Shares of Target Hospitality Corp. (NASDAQ:TH)marketbeat.com - April 13 at 4:31 AMTarget Hospitality Corp. (NASDAQ:TH) Short Interest Down 37.7% in Marchmarketbeat.com - April 12 at 3:16 PMHold Rating Maintained Amidst Acquisition Bid and Growth Prospects for Target Hospitalitymarkets.businessinsider.com - April 12 at 11:57 AMThe Analyst Landscape: 4 Takes On Target Hospitalitymarkets.businessinsider.com - April 12 at 11:57 AMDocuSign upgraded, Arista downgraded: Wall Street's top analyst callsfinance.yahoo.com - April 12 at 11:57 AMTarget Hospitality's (TH) "Hold" Rating Reiterated at Stifel Nicolausmarketbeat.com - April 12 at 8:23 AMTarget Hospitality Announces Partnership with Chard Métis Dene Groupfinance.yahoo.com - April 12 at 6:57 AMTarget Hospitality Announces Partnership with Chard Métis Dene Groupprnewswire.com - April 12 at 6:45 AMRosie Holidays opens new gallery to mark its 50th anniversaryfbcnews.com.fj - April 11 at 10:48 PMWall Street Favorites: 3 Under-$20 Stocks With Strong Buy Ratings for April 2024investorplace.com - April 11 at 1:46 PMTarget Hospitality Corp (TH)investing.com - April 11 at 12:47 PMKent Lake Capital LLC Lowers Position in Target Hospitality Corp. (NASDAQ:TH)marketbeat.com - April 6 at 7:36 PMWhy Target Hospitality Stock Surged Higher This Weekfool.com - March 28 at 1:31 PMTarget Hospitality Corp.cnn.com - March 27 at 10:24 AMTarget Hospitality's (TH) "Buy" Rating Reaffirmed at Stifel Nicolausmarketbeat.com - March 26 at 10:46 AMArrow offers to buy remaining stake Target Hospitalitymsn.com - March 25 at 7:51 PMTarget Hospitality jumps after $10.80 a share takeover offermsn.com - March 25 at 7:51 PMTarget Hospitality (NASDAQ:TH) PT Lowered to $10.00marketbeat.com - March 25 at 8:48 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesDisney Stock Catches 3 Upgrades In a Single WeekMarch 28, 2024 10:27 AMView Disney Stock Catches 3 Upgrades In a Single Week2 Stocks to Buy on The Dip: One a Value, the Other High-YieldingApril 12, 2024 7:32 AMView 2 Stocks to Buy on The Dip: One a Value, the Other High-YieldingSilver Soars: Here's How to Gain ExposureApril 10, 2024 7:00 AMView Silver Soars: Here's How to Gain ExposureDocuSign and The Case for 66% Upside April 16, 2024 10:20 AMView DocuSign and The Case for 66% Upside GameStop Stock Downtrend Is Intact: The End Game Draws NearMarch 27, 2024 8:47 AMView GameStop Stock Downtrend Is Intact: The End Game Draws NearAll Headlines Company DescriptionsAngion BiomedicaNASDAQ:ANGNAngion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.NexImmuneNASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Sensei BiotherapeuticsNASDAQ:SNSESensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Target HospitalityNASDAQ:THTarget Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.